Actively Recruiting
A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke
Led by Xuanwu Hospital, Beijing · Updated on 2026-02-19
2600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate intravenous thrombolysis treatments given beyond the usual time window for people who have experienced an acute ischemic stroke. The study is observational and collects data from multiple centers to better understand outcomes for patients treated between 4.5 and 24 hours after stroke onset. It focuses on comparing two thrombolytic agents, Alteplase and Tenecteplase, for stroke management in this extended time frame. Participants received either Alteplase or Tenecteplase within 4.5 to 24 hours after the stroke symptoms began. The study groups consist of those treated with Alteplase and those treated with Tenecteplase, and researchers observe the effects without assigning treatments themselves. This retrospective design allows gathering clinical data on the timing and type of thrombolysis used in real-world settings. During the study, researchers review clinical information such as modified Rankin Scale (mRS) scores and National Institutes of Health Stroke Scale (NIHSS) scores at specific time points, including 24 hours and 90 days after treatment. They measure functional outcomes, mortality rates, and risks like symptomatic intracranial hemorrhage. This data collection helps assess recovery and safety profiles of the treatments over time, with a focus on long-term outcomes at about three months after stroke onset.
CONDITIONS
Brief Title
A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute ischemic stroke, regardless of gender
- Age 18 years or older
- Treatment given between 4.5 and 24 hours from stroke onset (defined as the last time patient was seen normal)
- Complete clinical data available including gender, age, mRS, NIHSS scores
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment event
Participants receive intravenous thrombolysis with Alteplase or Tenecteplase for acute ischemic stroke between 4.5 and 24 hours from stroke onset.
1 treatment visit (in-person)
Duration - Up to 90 days
Participants are monitored for recovery and safety outcomes following treatment.
Follow-up visits at 24 hours, within 36 hours, and at 90 days
Trial Site Locations
Total: 1 location
1
Xuanwu Hospital Capital Medical University, Beijing, Beijing 100053
Beijing, China, 100053
Actively Recruiting
Research Team
X
Xin Xing, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here